Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- AMED Launches Study on Evaluating the Quality and Safety of Nucleic Acid Medicines to Promote Their Development
July 25, 2018
- Discussions Needed for “Biosame” Products: MHLW Official
July 24, 2018
- Lilly’s Breast Cancer Med Abemaciclib Up for MHLW Panel Review on Aug. 3
July 23, 2018
- Lawmakers Question Rationale for PMD Law Amendment as LDP Launches Debate
July 19, 2018
- Scope of Japan-EU GMP Mutual Recognition Agreement for Pharmaceuticals Expanded: MHLW
July 19, 2018
- Boehringer’s DPP-4/SGLT2 Combo Up for MHLW Panel Review on July 27
July 17, 2018
- MHLW to Introduce Guidelines for Sales Reps’ Activities, Calling for the Creation of Supervising Offices
July 17, 2018
- New Medical Infrastructure Law to Pave Way for Database on 50 Million People: Govt Official
July 13, 2018
- MHLW Orders Removal of Pregnancy Contraindications for 3 Immunosuppressants
July 12, 2018
- MHLW Selects 9 Priority Prefectures for Generic Promotion Project, but Leaves Tokyo Out
July 12, 2018
- Generic Makers Should Shift to Biologics Biz for Survival: MHLW Official
July 11, 2018
- MHLW Official Expounds on “Authorized Biosimilar” Pricing, 50% Generic Rule Applies for “Biosame” Products
July 11, 2018
- Cabinet OKs FY2019 Budget Guidelines, Allows Request for 600 Billion Yen Social Security Cost Rise
July 11, 2018
- Prices for High-Cost Techs Will Settle Down as They Penetrate Market with Public Health Coverage: MHLW Bureau Chief
July 10, 2018
- Tokyo Govt to Launch Support Program for Drug Discovery Startups to Solve Obstacles to Fundraising, IP Strategy
July 10, 2018
- Reduce Dose, or Discontinue Biologics for Patients with Low RA Disease Activity: Report
July 9, 2018
- Govt Dodges Lawmaker Inquiry on Timing of 2019 Drug Price Revision
July 9, 2018
- LDP Lawmakers to Sort Out Life Science Issues over This Summer
July 6, 2018
- Council OKs Public Knowledge-Based Submissions for New Azathioprine, Temozolomide Indications
July 5, 2018
- Govt Likely to Allow 600 Billion Yen Rise for FY2019 Social Security Budget Request
July 4, 2018
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…